Element Nutritional Sciences Inc (TSE:MUSL) has released an update.
Promino Nutritional Sciences Inc. is set to begin preclinical trials led by Dr. Patrick Gunning to evaluate the effectiveness of its product Promino when used in conjunction with GLP-1 based weight loss drugs like Ozempic. The trials aim to address the significant muscle loss associated with GLP-1 treatments, which affect up to 6% of American adults using these drugs for weight management. With GLP-1 drugs becoming a $35 billion industry and prescriptions soaring, Promino’s research could have substantial implications for improving health outcomes during weight loss.
For further insights into TSE:MUSL stock, check out TipRanks’ Stock Analysis page.
